XML 19 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2020
Jun. 30, 2019
Cash flows from operating activities      
Net (loss) income $ (16,530,700) $ (22,815,143) $ 9,020,479
Adjustments to reconcile net income (loss) to net cash provided by operating activities:      
Depreciation and amortization 14,705,598 28,609,982 5,889,627
Stock based compensation   8,998,180 250,783
Amortization of debt issuance costs   663,294 203,702
Fair value change in tax receivable agreement liability   10,580,421  
Fair value change in other assets and liabilities   708,622  
Deferred tax expense   (5,012,717)  
Change in accounts receivable   1,213,666 (1,040,466)
Change in related party receivable   563,084  
Change in prepaid expenses and other   178,443 (48,015)
Change in accounts payable   486,986 (1,207,963)
Change in related party payable   (14,467,759)  
Change in accrued expenses and other   (458,152) (4,908,835)
Change in other liabilities   168,852  
Net cash provided by operating activities   9,417,759 8,159,312
Cash flows from investing activities      
Purchases of property and equipment   (539,008) (182,931)
Purchases of software   (7,202,987) (3,572,077)
Net cash used in investing activities   (43,728,473) (3,755,008)
Cash flows from financing activities      
Change in line of credit   (10,000,000)  
Issuance of long-term debt   60,425,983  
Payments on long-term debt   (2,965,162) (2,450,000)
Exercise of warrants 51,800,000 55,327,515  
Redemption of Post-Merger Repay Units   (98,800,000)  
Distributions to Members     (6,904,991)
Payment of loan costs   (1,861,817)  
Net cash provided by (used in) financing activities   176,118,827 (9,354,991)
Increase (decrease) in cash, cash equivalents and restricted cash   141,808,113 (4,950,687)
Cash, cash equivalents and restricted cash at beginning of period   37,901,117 23,262,058
Cash, cash equivalents and restricted cash at end of period $ 179,709,230 179,709,230 18,311,371
Cash paid during the year for:      
Interest   6,433,715 $ 2,714,926
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES      
Acquisition of Ventanex in exchange for contingent consideration   10,800,000  
Ventanex      
Cash flows from investing activities      
Acquisition, net of cash and restricted cash acquired   (35,521,024)  
APS Payments      
Cash flows from investing activities      
Acquisition, net of cash and restricted cash acquired   (465,454)  
Class A Common Stock      
Cash flows from financing activities      
Public issuance of Class A Common Stock   $ 173,992,308